Clinical Trials Browser

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular, Neoplasms

Carcinoma, Hepatocellular

Spinocerebellar Degenerations, Colorectal Neoplasms

Stomach Neoplasms

Neoplasm Metastasis

Rectal Neoplasms

Lymphoma, T-Cell, Peripheral

Triple Negative Breast Neoplasms

Carcinoma, Hepatocellular

Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Resectable NSCLC

Stomach Neoplasms

Carcinoma, Hepatocellular

Colorectal Neoplasms

Triple Negative Breast Neoplasms

Nasopharyngeal Carcinoma

Rectal Neoplasms

Endometrial Neoplasms

Colonic Neoplasms

Carcinoma, Hepatocellular

Neoplasms, Unknown Primary

Colorectal Neoplasms

Pancreatic Neoplasms

Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Squamous Cell Carcinoma of Head and Neck

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Triple Negative Breast Neoplasms

Cholangiocarcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Esophageal Neoplasms

Appendiceal Neoplasms, Neoplasm Metastasis

Lung Squamous Cell Carcinoma

Carcinoma, Hepatocellular

Gastric Adenocarcinoma

Carcinoma, Hepatocellular

Breast Neoplasms

Locally Advanced Rectal Cancer

Uterine Cervical Neoplasms, Esophageal Neoplasms, Endometrial Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Uterine Cervical Neoplasms

Carcinoma, Hepatocellular

Rectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Pancreatic Neoplasms

Hemangiosarcoma

Clinical Trials

A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.

A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma

Study of ABO2102 in KRAS-Mutated Solid Tumors

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

Sincerely20

NeoSACT

Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)

Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

K-NADIR

A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma

A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC

FEMUS

TRIUNITE-08

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

Sintilimab in Cancer of Unknown Primary

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer

A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer

Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma

Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

CTONG 2508

SACTION 2501

ESO-Nanjing7

Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

ARTEMIS-GC3

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

CISN-L

NLCCRIT-LARC

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

Remission

Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC

A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer

A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study